Bit Digital CEO: I have increased holdings in ETH, and I am responsible for making smart capital allocation decisions for our clients
Odaily reported that Sam Tabar, CEO of the Nasdaq-listed company Bit Digital, announced on X that he has purchased more ETH.
Sam Tabar explained: “Many people, after seeing ETH’s price performance over the past two years, have concluded that it’s finished. But I believe they are focusing on the wrong catalyst. The repricing of ETH should never be built upon a retail narrative. For an asset supported by such a vast infrastructure, that narrative is simply too fragile. The real catalyst is institutional demand. And the pace of institutional demand has never operated according to sentiments on social media. It will only materialize when the compliance framework is ready, the custody system has been established, and the regulatory environment is stable enough for a CFO to give the final sign-off. And that moment is, in fact, closer than what the market price suggests.”
He added: “I hold ETH because I have a fiduciary obligation to make smart capital allocation decisions. At the price at which I bought in, ETH meets this standard.”
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Analyst Gu Jingci: Follow the trend and adapt flexibly
XRP Ledger adds account control feature, enabling enterprises to manage assets offline.
BUZZ - Goldman Sachs says the price cap on cancer drugs has limited impact on Indian hospitals
October 9 – Goldman Sachs pointed out that India's implementation of a 30% profit margin cap on non-scheduled anticancer drugs (link) will have limited impact on hospitals. The report states that, based on preliminary discussions with hospital chain groups, such drugs account for less than 5% of hospital revenue and 2% to 2.5% of operating profit. The report adds that hospitals can offset the losses by slightly adjusting service charges, such as administration fees. According to a government notice, an expert committee will finalize the list of drugs to be brought under regulation. Driven by the anticipated price cap, the share prices of Max Healthcare MAXE.NS, Apollo Hospitals APLH.NS, and Fortis Healthcare FOHE.NS rose by 1.6% to 2.5%. Previously, since September 30, these stocks had collectively declined by 11% to 11.5%. Year-to-date, FOHE and MAXE are down 11.7% and 14.8%, respectively, while APLH has risen by 11%. (To assist non-English speakers, Reuters provides automated translations of its reports into several other languages. Due to potential errors or missing context in automated translations, Reuters does not guarantee the accuracy of automatic translation texts and offers them solely for readers’ convenience. Reuters accepts no responsibility for any damage or loss caused by using these automated translation features.)
Adding insult to injury! Japanese electronics giant Nidec downgraded by UBS, stock price plunges over 9% and approaches an 11-month low
UBS has downgraded Nidec's rating from "Buy" to "Neutral" and lowered its target price from 2,800 yen to 2,400 yen, citing a more challenging market environment.
Crypto prices
More
